SCHEDULE: Forbion Funds Update NewAmsterdam Pharma Stake

Forbion Capital Partners and related entities updated their beneficial ownership in NewAmsterdam Pharma Company N.V., collectively holding 9.4% of outstanding shares.

Summary

• Forbion Capital Fund IV Cooperatief U.A. and Forbion IV Management B.V. beneficially own 5,930,781 Ordinary Shares, representing approximately 5.3% of the outstanding shares.
• Forbion Growth Opportunities Fund I Cooperatief U.A. and Forbion Growth Management B.V. beneficially own 4,648,025 Ordinary Shares, representing approximately 4.1% of the outstanding shares.
• ForGrowth NAP B.V. beneficially owns an aggregate of 10,578,806 Ordinary Shares, representing approximately 9.4% of the outstanding shares.
• The total outstanding Ordinary Shares used for percentage calculation is 112,628,458, as reported by NewAmsterdam Pharma Company N.V. in its Quarterly Report on Form 10-Q filed on August 6, 2025.
• The 10,578,806 Ordinary Shares held by ForGrowth NAP B.V. include 9,926,633 Ordinary Shares allocable to Forbion Growth I and Forbion IV through ForGrowth's interest in PoolCo.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding company performance or future prospects.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by a significant investor group in a publicly traded pharmaceutical company, NewAmsterdam Pharma Company N.V. It reflects the ongoing investment and stake held by venture capital funds specializing in life sciences.

Legal Proceedings

• NA

Related Party Transactions

• The beneficial ownership structure involves several related Forbion entities, including Forbion Capital Fund IV Cooperatief U.A., Forbion Growth Opportunities Fund I Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Management B.V., and ForGrowth NAP B.V., which collectively hold shares in NewAmsterdam Pharma Company N.V. through a pooled interest.

Stakeholder Impact

• Shareholders are informed of the current beneficial ownership stake held by Forbion Capital Partners and its related entities, providing transparency regarding significant institutional holdings.

Key Dates

Keywords

NewAmsterdam Pharma, Forbion, Schedule 13D, beneficial ownership, ordinary shares, N62509109, biotechnology, pharmaceuticals